Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Janux Therapeutics (JANX) Capital Expenditures (2020 - 2025)

Historic Capital Expenditures for Janux Therapeutics (JANX) over the last 6 years, with Q3 2025 value amounting to $93000.0.

  • Janux Therapeutics' Capital Expenditures rose 27200.0% to $93000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $979000.0, marking a year-over-year increase of 1766.83%. This contributed to the annual value of $359000.0 for FY2024, which is 8059.46% down from last year.
  • According to the latest figures from Q3 2025, Janux Therapeutics' Capital Expenditures is $93000.0, which was up 27200.0% from $473000.0 recorded in Q2 2025.
  • Over the past 5 years, Janux Therapeutics' Capital Expenditures peaked at $2.5 million during Q3 2022, and registered a low of $25000.0 during Q3 2024.
  • In the last 5 years, Janux Therapeutics' Capital Expenditures had a median value of $470000.0 in 2023 and averaged $582789.5.
  • Per our database at Business Quant, Janux Therapeutics' Capital Expenditures soared by 6280000.0% in 2021 and then plummeted by 9468.09% in 2024.
  • Janux Therapeutics' Capital Expenditures (Quarter) stood at $629000.0 in 2021, then soared by 226.87% to $2.1 million in 2022, then tumbled by 74.95% to $515000.0 in 2023, then plummeted by 91.84% to $42000.0 in 2024, then surged by 121.43% to $93000.0 in 2025.
  • Its Capital Expenditures stands at $93000.0 for Q3 2025, versus $473000.0 for Q2 2025 and $371000.0 for Q1 2025.